NCT04121676View on ClinicalTrials.gov

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

February 22, 2024

Study Completion Date

November 30, 2024

Conditions
Advanced Cancer
Interventions
DRUG

AGEN2373

An Anti-CD137 Monoclonal Antibody

DRUG

Botensilimab

Anti-CTLA-4 Monoclonal Antibody

Trial Locations (12)

10032

Columbia University, New York

14203

Roswell Park Comprehensive Cancer Care, Buffalo

15232

UPMC, Pittsburgh

33146

University of Miami, Coral Gables

33612

Moffitt Cancer Center, Tampa

75230

Mary Crowley Cancer Research Center, Dallas

78229

NEXT Oncology, San Antonio

80045

University of Colorado Anschutz Medical Campus, Aurora

90033

University of Southern California Norris Comprehensive Cancer Center/ Hoag, Los Angeles

97213

Providence Cancer Institute, Portland

98109

University of Washington, Seattle

07960

Atlantic Health System, Morristown

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY